Literature DB >> 20027193

Aldosterone and arterial hypertension.

Andreas Tomaschitz1, Stefan Pilz, Eberhard Ritz, Barbara Obermayer-Pietsch, Thomas R Pieber.   

Abstract

In the setting of primary aldosteronism, elevated aldosterone levels are associated with increased blood pressure. Aldosterone concentrations within the normal range, however, can also alter blood pressure. Furthermore, the aldosterone-to-renin ratio, an indicator of aldosterone excess, is associated with hypertension, even in patients without excessive absolute aldosterone levels. In this Review we assess the data on the role of aldosterone in the development and maintenance of hypertension. We provide an overview of the complex crosstalk between genetic and environmental factors, and about aldosterone-mediated arterial hypertension and target organ damage. The discussion is organized according to major targets of aldosterone action: the collecting duct in the kidney, the vasculature and the central nervous system. The antihypertensive efficacy of mineralocorticoid-receptor blockers, even in patients with aldosterone values in the normal range, supports the evidence that aldosterone plays a part in blood pressure elevation in the absence of primary aldosteronism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20027193     DOI: 10.1038/nrendo.2009.263

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  146 in total

1.  Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes.

Authors:  E Harada; M Yoshimura; H Yasue; O Nakagawa; M Nakagawa; M Harada; Y Mizuno; M Nakayama; Y Shimasaki; T Ito; S Nakamura; K Kuwahara; Y Saito; K Nakao; H Ogawa
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

Review 2.  Aldosterone and vascular inflammation.

Authors:  Nancy J Brown
Journal:  Hypertension       Date:  2008-01-02       Impact factor: 10.190

Review 3.  Rapid actions of aldosterone in vascular health and disease--friend or foe?

Authors:  Ole Skøtt; Torben R Uhrenholt; Jeppe Schjerning; Pernille B L Hansen; Lasse E Rasmussen; Boye L Jensen
Journal:  Pharmacol Ther       Date:  2006-01-18       Impact factor: 12.310

4.  Plasma aldosterone is independently associated with the metabolic syndrome.

Authors:  Murielle Bochud; Jürg Nussberger; Pascal Bovet; Marc R Maillard; Robert C Elston; Fred Paccaud; Conrad Shamlaye; Michel Burnier
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

5.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

6.  CYP11B2 gene haplotypes independently and in concurrence with aldosterone and aldosterone to renin ratio increase the risk of hypertension.

Authors:  Azim Nejatizadeh; Rahul Kumar; Tsering Stobdan; A K Goyal; Mohit Gupta; S Tyagi; S K Jain; M A Qadar Pasha
Journal:  Clin Biochem       Date:  2009-09-26       Impact factor: 3.281

7.  Serum aldosterone and protein-binding variables in Yanomama Indians: a no-salt culture as compared to partially acculturated Guaymi Indians.

Authors:  W Nowaczynski; W J Oliver; J V Neel
Journal:  Clin Physiol Biochem       Date:  1985

8.  Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Authors:  William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

9.  Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.

Authors:  Toshio Imanishi; Hideyuki Ikejima; Hiroto Tsujioka; Akio Kuroi; Katsunobu Kobayashi; Yasuteru Muragaki; Seiichi Mochizuki; Masami Goto; Kiyoshi Yoshida; Takashi Akasaka
Journal:  Hypertension       Date:  2008-01-28       Impact factor: 10.190

10.  Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.

Authors:  Takao Saruta; Shigeru Kageyama; Toshio Ogihara; Kunio Hiwada; Masayo Ogawa; Kazuji Tawara; Marjorie Gatlin; Susan Garthwaite; Richard Bittman; Jeffrey Patrick
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

View more
  31 in total

1.  Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Whitney Petrilli; Clare London; Gui-Bai Liang; Jim Tata; Qingzhong Hu; Lina Yin; Chris J van Koppen; Rolf W Hartmann; Mary Struthers; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Yusheng Xiong
Journal:  ACS Med Chem Lett       Date:  2015-07-17       Impact factor: 4.345

Review 2.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

3.  Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Authors:  Scott B Hoyt; Min K Park; Clare London; Yusheng Xiong; Jim Tata; D Jonathan Bennett; Andrew Cooke; Jiaqiang Cai; Emma Carswell; John Robinson; John MacLean; Lindsay Brown; Simone Belshaw; Thomas R Clarkson; Kun Liu; Gui-Bai Liang; Mary Struthers; Doris Cully; Tom Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Tian-Quan Cai; Sloan Stribling; Lee-Yuh Pai; Xiuying Ma; Joe Metzger; Andreas Verras; Daniel McMasters; Qing Chen; Elaine Tung; Wei Tang; Gino Salituro; Nicole Buist; Jeff Kuethe; Nelo Rivera; Joe Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Maxwell; Mike Lassman; Theresa McLaughlin; Jose Castro-Perez; Daphne Szeto; Gail Forrest; Richard Hajdu; Mark Rosenbach; Amjad Ali
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

4.  Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.

Authors:  Whitney L Petrilli; Scott B Hoyt; Clare London; Daniel McMasters; Andreas Verras; Mary Struthers; Doris Cully; Thomas Wisniewski; Ning Ren; Charlene Bopp; Andrea Sok; Qing Chen; Ying Li; Elaine Tung; Wei Tang; Gino Salituro; Ian Knemeyer; Bindhu Karanam; Joseph Clemas; Gaochao Zhou; Jack Gibson; Carrie Ann Shipley; Douglas J MacNeil; Ruth Duffy; James R Tata; Feroze Ujjainwalla; Amjad Ali; Yusheng Xiong
Journal:  ACS Med Chem Lett       Date:  2016-11-22       Impact factor: 4.345

Review 5.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

6.  NADPH oxidase-derived H(2)O(2) contributes to angiotensin II-induced aldosterone synthesis in human and rat adrenal cortical cells.

Authors:  Senthilkumar B Rajamohan; Gayatri Raghuraman; Nanduri R Prabhakar; Ganesh K Kumar
Journal:  Antioxid Redox Signal       Date:  2012-03-02       Impact factor: 8.401

7.  Structural insights into aldosterone synthase substrate specificity and targeted inhibition.

Authors:  Natallia Strushkevich; Andrei A Gilep; Limin Shen; Cheryl H Arrowsmith; Aled M Edwards; Sergey A Usanov; Hee-Won Park
Journal:  Mol Endocrinol       Date:  2013-01-15

Review 8.  Oxidative stress in hypertension: role of the kidney.

Authors:  Magali Araujo; Christopher S Wilcox
Journal:  Antioxid Redox Signal       Date:  2013-04-30       Impact factor: 8.401

9.  Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Elisabeth I Heath; David C Smith; Dana Rathkopf; Amanda L Blackford; Daniel C Danila; Serina King; Anja Frost; A Seun Ajiboye; Ming Zhao; Janet Mendonca; Sushant K Kachhap; Michelle A Rudek; Michael A Carducci
Journal:  Oncologist       Date:  2013-01-22

10.  Effect of morin, a flavonoid against DOCA-salt hypertensive rats: a dose dependent study.

Authors:  P Prahalathan; S Kumar; B Raja
Journal:  Asian Pac J Trop Biomed       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.